Gratus Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $10.3M | Buy |
369,718
+26,534
| +8% | +$731K | 0.41% | 70 |
|
|
2024
Q1 | $9.52M | Buy |
343,184
+10,056
| +3% | +$279K | 0.44% | 72 |
|
|
2023
Q4 | $9.59M | Sell |
333,128
-8,370
| -2% | -$253K | 0.54% | 62 |
|
|
2023
Q3 | $11.3M | Buy |
341,498
+5,439
| +2% | +$192K | 0.77% | 42 |
|
|
2023
Q2 | $12.3M | Buy |
336,059
+12,548
| +4% | +$488K | 0.84% | 39 |
|
|
2023
Q1 | $13.2M | Sell |
323,511
-1,316
| -0.4% | -$56.8K | 1.01% | 37 |
|
|
2022
Q4 | $16.6M | Buy |
324,827
+15,790
| +5% | +$757K | 1.37% | 20 |
|
|
2022
Q3 | $13.5M | Buy |
309,037
+25,854
| +9% | +$1.26M | 1.43% | 24 |
|
|
2022
Q2 | $14.8M | Buy |
283,183
+10,857
| +4% | +$553K | 1.66% | 15 |
|
|
2022
Q1 | $14.1M | Buy |
272,326
+11,780
| +5% | +$611K | 1.35% | 22 |
|
|
2021
Q4 | $15.4M | Buy |
260,546
+8,262
| +3% | +$409K | 1.42% | 21 |
|
|
2021
Q3 | $10.9M | Buy |
252,284
+17,832
| +8% | +$790K | 1.16% | 32 |
|
|
2021
Q2 | $9.18M | Buy |
234,452
+19,697
| +9% | +$766K | 1.02% | 42 |
|
|
2021
Q1 | $7.78M | Buy |
214,755
+6,962
| +3% | +$247K | 0.93% | 44 |
|
|
2020
Q4 | $7.65M | Sell |
207,793
-2,396
| -1% | -$87.9K | 1.02% | 45 |
|
|
2020
Q3 | $7.32M | Buy |
210,189
+10,689
| +5% | +$375K | 1.14% | 34 |
|
|
2020
Q2 | $6.19M | Sell |
199,500
-668
| -0.3% | -$22.7K | 1.04% | 43 |
|
|
2020
Q1 | $6.2M | Buy |
200,168
+169,680
| +557% | +$5.78M | 1.16% | 30 |
|
|
2019
Q4 | $1.13M | Buy |
30,488
+4
| +0% | +$142 | 0.17% | 108 |
|
|
2019
Q3 | $1.04M | Sell |
30,484
-146,006
| -83% | -$5.31M | 0.17% | 107 |
|
|
2019
Q2 | $7.25M | Buy |
176,490
+2,339
| +1% | +$92.9K | 1.18% | 32 |
|
|
2019
Q1 | $7.02M | Sell |
174,151
-41,442
| -19% | -$1.66M | 1.18% | 33 |
|
|
2018
Q4 | $8.93M | Buy |
215,593
+4,224
| +2% | +$175K | 1.83% | 9 |
|
|
2018
Q3 | $8.84M | Buy |
211,369
+4,553
| +2% | +$175K | 1.21% | 14 |
|
|
2018
Q2 | $7.12M | Sell |
206,816
-1,208
| -0.6% | -$41.3K | 1.06% | 23 |
|
|
2018
Q1 | $7M | Sell |
208,024
-21,428
| -9% | -$737K | 1.01% | 22 |
|
|
2017
Q4 | $7.88M | Buy |
229,452
+182,270
| +386% | +$6.22M | 1.02% | 22 |
|
|
2017
Q3 | $1.6M | Buy |
47,182
+27
| +0.1% | +$868 | 0.22% | 88 |
|
|
2017
Q2 | $1.5M | Sell |
47,155
-320
| -0.7% | -$10.1K | 0.21% | 88 |
|
|
2017
Q1 | $1.54M | Buy |
47,475
+395
| +0.8% | +$12.5K | 0.22% | 89 |
|
|
2016
Q4 | $1.45M | Sell |
47,080
-1,641
| -3% | -$50.1K | 0.22% | 91 |
|
|
2016
Q3 | $1.57M | Buy |
48,721
+427
| +0.9% | +$14.3K | 0.23% | 88 |
|
|
2016
Q2 | $1.61M | Buy |
+48,294
| New | +$1.54M | 0.24% | 84 |
|
Other funds holding PFE
Gratus Capital's PFE Position: Q2 2024 in Review
Gratus Capital increased its Pfizer (PFE) stake by 7.7% in Q2 2024, buying an estimated $731K and bringing the position to 369,718 shares worth $10.3M. The position accounts for 0.41% of the portfolio, ranked #70.
Gratus Capital first reported a position in PFE in Q2 2016 and has held it in 33 quarters since. The position peaked at $16.6M in Q4 2022. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Gratus Capital held 369,718 shares of Pfizer worth $10.3M as of Q2 2024.
- Gratus Capital bought 26,534 Pfizer shares in Q2 2024, an estimated $731K.
- Pfizer made up 0.41% of Gratus Capital's portfolio in Q2 2024, its #70 holding.
- Gratus Capital first reported a position in Pfizer in Q2 2016 and has held it in 33 quarters since.
- Gratus Capital's Pfizer position peaked at $16.6M in Q4 2022.
- 2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.